Substantial Impairment of Voriconazole Clearance by High-Dose Meropenem in a Patient With Renal Failure

Overview

Journal Clin Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2017 May 16

PMID 28505263

Citations 5

Authors

Mazyar Mahmoudi

Thorsten Brenner

Gencay Hatiboglu

Jurgen Burhenne

Johanna Weiss

Markus A Weigand

Walter E Haefeli

Affiliations

Soon will be listed here.

Abstract

A critically ill patient with multiple postoperative infections repeatedly required profound voriconazole dose reductions whenever high-dose meropenem was added. Subsequent in vitro assessment confirmed inhibition of cytochrome P450 (CYP) 2C19 and CYP3A4 by meropenem, suggesting that during meropenem treatment, narrow therapeutic index drugs metabolized by these CYPs require close monitoring.

Citing Articles

[Drug-drug interactions in critically ill patients].

Bellmann R, Weiler S Med Klin Intensivmed Notfmed. 2024; .

PMID: 39607462 DOI: 10.1007/s00063-024-01214-z.

Developmental Pharmacokinetics of Antibiotics Used in Neonatal ICU: Focus on Preterm Infants.

Butranova O, Ushkalova E, Zyryanov S, Chenkurov M Biomedicines. 2023; 11(3).

PMID: 36979919 PMC: 10046592. DOI: 10.3390/biomedicines11030940.

The Issue of Pharmacokinetic-Driven Drug-Drug Interactions of Antibiotics: A Narrative Review.

Cattaneo D, Gervasoni C, Corona A Antibiotics (Basel). 2022; 11(10).

PMID: 36290068 PMC: 9598487. DOI: 10.3390/antibiotics11101410.

C/MIC > 4: A Potential Instrument to Predict the Efficacy of Meropenem.

Zhao Y, Xiao C, Hou J, Wu J, Xiao Y, Zhang B Antibiotics (Basel). 2022; 11(5).

PMID: 35625314 PMC: 9137711. DOI: 10.3390/antibiotics11050670.

Poor response to rivaroxaban in nephrotic syndrome with acute deep vein thrombosis: A case report.

Li Y, Chen Y, Qi X, Hu B, Du Q, Qian Y Medicine (Baltimore). 2019; 98(31):e16585.

PMID: 31374026 PMC: 6709193. DOI: 10.1097/MD.0000000000016585.